Conditional proteolysis gene silencing targeting chimera and methods of use thereof

The Conditional Proteolysis Gene silencing Targeting Chimera (PROGENTAC) addresses the limitations of existing protein regulation methods by integrating siRNA/ASO/nucleic acid-based prodrugs with DNA-based proteolysis-targeting chimeras for targeted protein degradation, enhancing specificity and efficacy in treating complex diseases like cancer and neurodegenerative disorders.

WO2025015018A1PCT designated stage expired Publication Date: 2025-01-16THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/037339
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-10
Filing Date
2024-07-10
Publication Date
2025-01-16

Smart Images

  • Figure US2024037339_16012025_PF_FP_ABST
    Figure US2024037339_16012025_PF_FP_ABST
Patent Text Reader

Abstract

Described herein are nucleic acid complexes for the targeted delivery of nucleic acid based prodrug and a nucleic acid based protein degrader which are conditionally activated in the presence of a selected gene target or chemical and biological stimuli. The nucleic acid complexes involve double-stranded DNA, XNA, DNA / XNA / RNA hybrids, and DNA nanostructures (Conditional Proteolysis Gene silencing Targeting Chimera "PROGENTAC").
Need to check novelty before this filing date? Find Prior Art

Description

CONDITIONAL PROTEOLYSIS GENE SILENCING TARGETING ClMETHODS OF USE THEREOFRELATED APPLICATIONSThis disclosure claims priority to U.S. Provisional Application No. 63 / 525,850, filed July 10, 2023, the contents of which are herein incorporated by reference in their entirety.SEQUENCE STATEMENTThe instant application contains a Sequence Listing, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said file is named G8118-0420 IjSL.xml and is 83,285 bytes in size.FIELD

[0001] The present invention relates to Conditional Proteolysis Gene silencing Targeting Chimera and methods of their use for treating diseases. The invention also includes methods of creating Conditional Proteolysis Gene silencing Targeting Chimera, and compositions comprising said Chimera. The Chimera comprise DNA nanostructures.BACKGROUND

[0002] The following includes information that may be useful in understanding the present invention. It is not an admission that any of the information, publications or documents specifically or implicitly referenced herein is prior art, or essential, to the presently described or claimed inventions. All publications, patents, related applications, and other written or electronic materials mentioned or identified herein are hereby incorporated herein by reference in their entirety. The information incorporated is as much a part of the application as filed as if all of the text and other content was repeated in the application, and should be treated as part of the text and content of the application as filed.

[0003] Alterations in gene expression levels, exceeding or falling short of specific thresholds, can critically affect phenotypes and give rise to numerous human diseases. Approximately 20,300 proteins comprise the human proteome, and the meticulous and rigorous regulation of these proteins is fundamental for preserving cellular and organismal equilibrium. Notably, many human diseases originate from aberrant proteins, especially those that are overexpressed or hyperactivated. Target protein level regulation within cells can be categorized into three primary tiers.

[0004] The first tier involves the development of gene-editing tcchnolo; CRISPR-Cas9, has revolutionized the field of genetics by providing the capability to alter the DNA sequence at precise locations in the genome. Although this technique offers exceptional precision and versatility, the use of CRISPR-Cas9 and other gene-editing techniques also poses several limitations, including lacking the capacity for dynamic target protein, efficiency, off- target effects, delivery, and potentially leading to genetic compensation.

[0005] The second tier pertains to translational level regulation, utilizing RNA interference (RNAi) technology. RNAi allows for the targeted silencing of specific genes, makes a very versatile tool that can be used in a wide range of research and therapeutic application, the process of designing and using RNAi molecules is relatively straightforward. However, here are some of the limitations, such as delivering RNAi molecules to cells, off-target effect, the effects of RNAi are typically temporary, and relatively low efficiency.

[0006] The third tier concerns protein-level regulation, employing the chemical knockdown of target proteins via Proteolysis-Targeting Chimeras (PROTAC). PROTACs consist of three main components: a target ligand, a linker, and an E3 ligase binder. By using a specific ligand and E3 ligase binder, a PROTAC can be designed to selectively target a specific protein for degradation, offering a targeted approach to modifying cellular function. This strategy provides selectively tagging disease-associated proteins for degradation, be highly potent to achieve the protein knockdown, target their undruggable proteins which is difficult to target with traditional small molecule inhibitors. PROTAC carries out its function through a catalytic cycle process, allowing PROTAC to operate effectively, even at low doses. Unlike conventional small molecule inhibitors, which compete for and occupy active sites, PROTAC work by inducing the degradation of entire proteins, rather than inhibiting their function, through a repeated, iterative mode of action. By degrading the entire protein, PROTAC can disrupt these non-enzymatic functions proteins, which could potentially have therapeutic benefits. While these individual strategies have demonstrated promising results for single target genes or proteins, their efficacy against multifactorial diseases, especially tumors, is somewhat limited.SUMMARY

[0007] The inventions described and claimed herein have many attributes and embodiments including, but not limited to, those set forth or described or referenced in this Summary. It is not intended to be all-inclusive and the inventions described and claimed hereinare not limited to or by the features or embodiments identified in this introducti included for purposes of illustration only and not restriction.

[0008] This disclosure provides for a Conditional Proteolysis Gene silencing Targeting Chimera (PROGENTAC).

[0009] This disclosure provides a method for reducing or diminishing the level of disease-associated proteins, thereby killing disease cells, such as cancer cells, or modulating and limiting the progression of other non-tumorous diseases. In some aspects, this disclosure provides a method for treating protein dysregulation-associated diseases, including cancer, neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, and Parkinson's disease, as well as metabolic disorders like diabetes and various forms of cardiovascular disease. The method involves targeting and degrading specific proteins known to be involved in these diseases. Examples of degradable proteins include Tumor Protein p53 (p53), Beta- Amyloid, Huntingtin, Human Epidermal Growth Factor Receptor 2 (HER2), Tau, Alpha-Synuclein, Epidermal Growth Factor Receptor (EGFR), Bromodomain-Containing Protein 4 (BRD4), Estrogen Receptor (ER), Androgen Receptor (AR), Myelocytomatosis Oncogene (c-Myc), and Cyclin-Dependent Kinases (CDK1-20). Additionally, active kinase complexes such as Cyclin- Dependent Kinase 4 / 6-Cyclin DI (CDK4 / 6-Cyclin DI), Cyclin-Dependent Kinase 9-Cyclin T1 (CDK9-Cyclin Tl), Cyclin-Dependent Kinase 1-Cyclin A (CDKl-Cyclin A), Cyclin-Dependent Kinase 2-Cyclin E (CDK2-Cyclin E), Cyclin-Dependent Kinase 12-18-Cyclin K (CDK12-18- Cyclin K), and Cyclin-Dependent Kinase 20-Cyclin L (CDK20-Cyclin L) are also targeted.DNA template targeted protein degradation (DTAC) is an established method which the inventors herein have expanded to use a DNA-based backbone design for targeted protein degradation. Described herein is a dual functional DTAC system capable of executing gene silencing through conditional trigger siRNA / shRNA / ASO / DNAzymes release and protein degradation via the DTAC mediated proteolytic pathway, a contract referred to as a Proteolysis Gene silencing Targeting Chimera (PROGENTAC).

[0010] Described herein is a method for the conditional activation of a dual-functional nucleic acid construct comprising gene- silencing siRNA / ASO / nucleic acid-based prodrugs and a protein degrader, a DNA-based proteolysis-targeting chimera. This dual functionality of conditional PROGENTAC offers several advantages, such as combating multidrug-resistant in complex diseases.[Oi l] The dual-functional PROGENT AC systems of this disclosure cc amalgamation of siRNA / ASO / nucleic acid-based prodrugs (e.g., DNAzyme) and PROTAC affords multiple advantages, including the following:

[0012] Comprehensive Coverage: siRNA operates by silencing genes at the mRNA level, whereas PROTAC degrades proteins post-translationally. This integrated approach guarantees wider coverage in targeting disease-causing agents, encompassing even traditionally 'undruggable' targets.

[0013] Enhanced Specificity: Both siRNA and PROTAC offer high target specificity. siRNA achieves this by aligning with sequences complementary to target mRNA, and PROTAC by specifically binding to its target protein. This focused approach can drastically diminish off- target effects, thereby augmenting treatment safety.

[0014] Combatting Resistant Strains: Drug resistance commonly surfaces due to mutations that modify the drug target. The flexibility to design siRNA against multiple mRNA sites and engineer PROTAC for different protein targets enables the treatments described herein to overcome said drug resistance.

[0015] In some aspects, this disclosure provides a nucleic acid-based system comprising: a first nucleic acid (NA) strand comprising: a first NA strand first sequence, and a first NA strand second sequence; and a second nucleic acid strand comprising: a second NA strand first sequence, a second NA strand second sequence, and a second NA strand third sequence, wherein the first NA strand first sequence is hybridized to the second NA strand first sequence, wherein the first NA strand second sequence is complementary to the second NA strand second sequence, and the second NA strand third sequence is complementary to the second NA strand second sequence, wherein the first NA strand second sequence and the second NA strand second sequence independently comprise an E3 ligase targeting agent or a Protein of Interest (POI) ligand, and wherein when the first NA strand second sequence comprises an E3 ligase targeting agent the second NA strand second sequence comprises a POI ligand, and when the first NA strand second sequence comprises a POI ligand, the second NA strand second sequence comprises an E3 ligase targeting agent,wherein the second NA strand second sequence and the second NA strand third separated by a hairpin loop sequence or a selectively cleavable linker.

[0016] In some aspects, the first NA strand can comprise DNA or RNA.

[0017] In some aspects, the second NA strand can comprise DNA or RNA or both discrete sequences of DNA and discrete sequences of RNA.

[0018] In some aspects, the second NA strand second sequence is hybridized to the second NA strand third sequence to form an inactive complex. The POI ligand and the E3 ligase targeting agent can be attached to modified bases which are at complementary base positions, or within ten base pairs away from each other.

[0019] In some aspects, first NA strand second sequence can be hybridized to the second NA strand second sequence to form an active complex. In some aspects, the first NA strand second sequence can be covalently hybridized to the second NA strand second sequence by photocleavable cross-links.

[0020] In some aspects, the second NA strand third sequence can be an antisense oligonucleotide, an aptamer drug, or a nucleic acid-based prodrug (e.g., DNAzyme).

[0021] In some aspects, this disclosure provides for a system comprising: a first nucleic acid (NA) strand comprising: a first NA strand first sequence, and a first NA strand second sequence; and a second nucleic acid strand comprising: a second NA strand first sequence, and a second NA strand second sequence, and a third strand NA sequence comprising: a third strand first sequence, a third strand second sequence, and a third strand third sequence; and a fourth strand NA sequence, wherein the first NA strand first sequence is hybridized to the second NA strand first sequence, wherein the first NA strand second sequence is complementary to the second NA strand second sequence, and the second NA strand third sequence is complementary to the second NA strand second sequence, wherein the first NA strand second sequence and the second NA strand second sequence independently comprise an E3 ligase targeting agent or a Protein of Interest (POI) ligand, andwherein when the first NA strand second sequence comprises an E3 ligase targe second NA strand second sequence comprises a POI ligand, and when the first NA strand second sequence comprises a POI ligand, the second NA strand second sequence comprises an E3 ligase targeting agent, and wherein the second NA strand second sequence is partially complementary to the third strand first sequence and the third strand second sequence in a splint-like manner, and wherein the third strand third sequence is complementary to the fourth strand NA sequence.

[0022] In some aspects, the fourth NA strand can be selected from siRNA or an antisense oligonucleotide sequence.

[0023] In some aspects, this disclosure provides for a method of killing a cancer cell, the method comprising: contacting a system as described herein in an inactive state with a cancer cell, and converting the system in an active state to a system in an active state, thereby presenting an antisense oligonucleotide to the cancer cell. In some aspects, the antisense oligonucleotide can be a knock-down sequence to the Protein of Interest. In some aspects, the conversion into an active state is performed by exposing UV light to the system. The UV light can range from 200 nm to about 400 nm. In some aspect, the UV light can be at a wavelength of about 365 nm.

[0024] In some aspects, this disclosure provides for a composition comprising a system as described herein and a pharmaceutically acceptable carrier. The composition can further comprise a therapeutic agent.DETAILED DESCRIPTIONBRIEF DESCRIPTION OF THE DRAWINGS

[0025] FIG. 1. Overview of DNA-based Proteolysis Targeting Chimera (DTAC) and their uses. DTAC can be utilized for multipurpose applications: 1) DNA / RNA / synthetic nucleotide-based programmable proteolysis targeting chimeras. 2) DTAC can be utilized both for drug development and therapeutic agents. 3) DNA scaffold can be used for finding new E3 ligases and protein inhibitors using DNA encoded library. 4) DNA scaffold can be used to control orientation and distance between E3-i and POI-i to facilitate ubiquitin transfer. 5) DNA scaffold can be used to improve aqueous solubility of inhibitors. 6) Conformationally locked DNA based programmable scaffold for conditional PROTACs.

[0026] FIG. 2. Overview of PROteolysis and GENe Silencing TArgeting Chimera (PROGENT AC). DNA templated spatially programmable DTAC with conditional / synergisticactivation for protein degradation and gene silencing. Inactive state of PR0GE1 two ligands for E3 ligase inhibitor and POI inhibitor in a spatially locked conformation holding an ASO / prodrug through a lock. Upon addition of external stimuli / keys such as DNA / RNA, pro tein / pep tide, small-molecule, or UV / visible / infrared light, the conformational lock is opened bringing the two ligands in proximity at optimal distance to form the active state for protein degradation and simultaneously releasing the ASO / prodrug inside cell / tissue / organ for gene silencing function.

[0027] FIG. 3. Overview of PROteolysis and GENe Silencing TArgeting Chimera (PROGENT AC). Another design for DNA templated spatially programmable DTAC with conditional / synergistic activation for protein degradation and gene silencing. Inactive state of PROGENTAC shows the two ligands for E3 ligase inhibitor and POI inhibitor in a spatially locked conformation holding an siRNA through two locks. Upon additional of external stimuli / keys such as DNA / RNA, protein / peptide, small-molecule, or UV / visible / infrared light, the conformational lock is opened bringing the two ligands in proximity at optimal distance to form the active state for protein degradation and simultaneously siRNA inside cell / tissue / organ for gene silencing function.

[0028] FIG. 4. Structures and chemical synthetic route for the Azido-PEG3- pomalidomide (E3i). Details in experimental section.

[0029] FIGS. 5A-5B. Nuclear magnetic resonance (NMR) characterization of in-house synthesized Azido-PEG3-pomalidomide (E3i) molecule (Solvent: CDCh). FIG. 5A 1 H NMR proton peaks shows corresponding peaks of pomalidomide hydrogen atoms. FIG. 5B 13 C NMR spectrum.

[0030] FIG. 6. ESI-MS spectra of synthesized Azido-PEG3-Pomalidomide: (Solvent: MeOH). Expected [M+Na]+= 453.41. Observed [M+Na]+= 453.15.

[0031] FIG. 7. Structures and chemical synthetic route for the Azido-PEG3-palbociclib (POIi). Details in experimental section.

[0032] FIGS. 8A-8B. NMR characterization of in-house synthesized Azido-PEG3- palbociclib (POIi) molecule (Solvent: CDCh). FIG. 8A 1H NMR proton peaks shows corresponding peaks of palbociclib hydrogen atoms. FIG. 8B 13C NMR spectrum.

[0033] FIG. 9. ESI-MS spectra of synthesized Azido-PEG3-palbociclib (POIi). (Solvent: MeOH). Expected [M+H]+= 605.32. Observed [M+H]+= 605.3322.

[0034] FIG. 10. Structure of amino-serinol phosphoramidite (purchased Research) for insertion of internal amine into the ssDNA sequences designed for DTAC library in FIG. 14B.

[0035] FIGS. 11A-11C. Schematic of conjugation of ligands (E3i and POIi) to DNA. FIG. 11A Synthesized amino-serinol phosphoramidite DNA (1) with CPG at 3’ is cleaved by treatment with 30% ammonia for 120 min for 2 h resulted in (2); FIG. 1 IB The free amino group reacts with DBCO-NHS ester and yields (3) in 3 h while mixed at 37°C; FIG. 11C Ultimately, a ligand pre-modified with azide handle is mixed with (3) by strain-promoted azidealkyne coupling reaction to yield the ligand conjugated DNA strand (4).

[0036] FIG. 12A shows the Negative mode ESI-MS characterization of amino-serinol phosphoramidte (iNEh) conjugated ssDNA strands to form the DTAC library (DTAC-Vl-iNH to V6-iNH). Strand A sequences (5’ to 3’) to be conjugated with E3-i ligand. Strand B sequences (5’ to 3’) to be conjugated with POI-i ligand.

[0037] FIG. 12B shows the negative mode ESI-MS characterization of amino-serinol phosphoramidte (iNEh) conjugated ssDNA strands to form the DTAC library (DTAC-Vl-iNH to V6-iNH). Strand A sequences (5’ to 3’) to be conjugated with E3-i ligand. Strand B sequences (5’ to 3’) to be conjugated with POI-i ligand.

[0038] The sequences are as follows:

[0039] SA-l-iNH: C*C*G*C AAT CTC CTT CAT C*G*C*iNH*C (SEQ ID NO: 1)

[0040] SB-l-iNH: G*iNH*G*C*G ATG AAG GAG ATT G*C*G*G (SEQ ID NO: 2)

[0041] SA-2-iNH: C*C*G*C AAT CTC CTT CAT C*iNH*G*C*C (SEQ ID NO: 3)

[0042] SA-2-iNH: G*G*C* iNHG ATG AAG GAG ATT G*C*G*G (SEQ ID NO: 4)

[0043] SA-3-iNH: C*C*G*C AAT CTC CTT CAT C*iNH*G*C*C (SEQ ID NO: 3)

[0044] SB-3-iNH: G*G*C*G ATG AAG GAG ATT G*iNH*C*G*G (SEQ ID NO: 5)

[0045] The asterisk (*) in the sequences described herein indiciate a phosphorothioate linkage.

[0046] FIG. 13A shows the negative mode ESI-MS characterization E3i and POIi conjugated DTAC library (DTAC-V1 to V6).

[0047] FIG. 13B shows the negative mode ESI-MS characterization E3i and POIi conjugated DTAC library (DTAC-V1 to V6). The sequences are as follows:

[0048] SA-l-E3-i: C*C*G*C AAT CTC CTT CAT C*G*C*E3-i*C (SEQ ID NO: 6)

[0049] SB-l-POI-i: G*POI-i*G*C*G ATG AAG GAG ATT G*C*G*G (SEQ ID NO:

[0050] SA-2-E3-i: C*C*G*C AAT CTC CTT CAT C*E3-i*G*C*C (S

[0051] SB-2-PPO-i: G*G*C*POI-iG ATG AAG GAG ATT G*C*G*G (SEQ ID NO: 9)

[0052] SA-3-E3-i: C*C*G*C AAT CTC E3-I CTT CAT C*G*C*C (SEQ ID NO: 10)

[0053] SB-3-POI-i: G*G*C*G ATG AAG POI-I GAG ATT G*C*G*G (SEQ ID NO: 11)

[0054] SA-4-E3-i: C*C*G*C AAT CTC CTT CE3-1AT C*G*C*C (SEQ ID NO: 12)

[0055] SB-4-POI-i: G*G*C*G ATG AAG POI-I GAG ATT G*C*G*G (SEQ ID NO: 11)

[0056] SA-5-E3-i: C*C*G*C E3-1AAT CTC CTT CAT C*G*C*C (SEQ ID NO: 13)

[0057] SB-5-POI-i: G*G*C*G ATG AAG POI-I GAG ATT G*C*G*G (SEQ ID NO: 11)

[0058] SA-6-E3-i: C*C*G*C AAT CTC CTT CAT C*E3-i*G*C*C (SEQ ID NO: 8)

[0059] SB-4-POI-i: G*G*C*G ATG AAG GAG ATT G*POI-i*C*G*G (SEQ ID NO: 14)

[0060] FIG. 14A. Annealing of DTAC. Schematic shows self-assembly of heterobifunctional DTAC via Watson-crick base pairing through annealing in buffer.

[0061] FIG. 14B. Screened spatially programmable DTAC library. A) Various DTAC designs prepared with different positions (VI to V3) increment in distance between E3 ligase and Protein of interest from VI to V6.

[0062] FIG. 15. 12% Native PAGE gel electrophoresis of the various DTACs from Version 1 to 6 showed well-formed DTAC library.

[0063] FIG. 16. Western blot analysis of CDK6 and CyclinDl proteins degradation in U251 cells treated with DTAC library (FIG. 11). The upper panels show the levels of CDK6 and CyclinDl protein after treatment with various concentrations (20 nM and 100 nM) of series DTACs (VI to V6) with unmodified DNA duplex as a control, and the lower panels display [3- actin as a loading control.

[0064] FIGS. 17A-17B. Dose- and Time-dependent Degradation of CDK6, CDK4 and CyclinDl in U251 Cells. CDK6, CDK4 and CyclinDl protein levels under different doses of DTAC-V03 and CDK6, CDK4 and CyclinDl protein levels in cells treated with 100 nM DTAC- V03 for specified time durations.

[0065] FIG. 18. Comparative analysis of CDK4 / 6 / Cyclin DI degradation by DTAC-V3, CP- 10, and palbociclib in U251 cells. Western blot analysis showing the protein levels of CDK6, CDK4, and Cyclin DI in U251 cells treated with DMSO (vehicle control), palbociclib(POIi), CP- 10, and DTAC-V3 at concentrations of 20 nM and 100 nM for 16 h< used as a loading control. The results demonstrate that CP- 10 effectively degrades CDK4 and CDK6 but not Cyclin DI, while palbociclib does not affect any of the proteins. In contrast, DTAC-V3 significantly degrades CDK4, CDK6, and Cyclin DI at both tested concentrations, indicating its superior efficacy in targeting the entire CDK4 / 6 / Cyclin DI protein complex.

[0066] FIG. 19. Mechanism of action of DTAC-V3. Western blot analysis showing inhibition of CDK4 / CDK6 / CyclinDl degradation when pre-incubation with 5 pM of proteasome inhibitor MG132 or PR171 for 2h followed by treatment of DTAC-V3 for lOh.

[0067] FIG. 20. Mechanism of action of DTAC-V3. Western blot analysis demonstrating the inhibition of CDK4 / 6 / Cyclin DI degradation upon co-treatment with pomalidomide (E3 ligase inhibitor, E3i) or palbociclib (CDK4 / 6 inhibitor, POIi) and DTAC-V3 for 16 hours.

[0068] FIG. 21. Antitumor Efficacy of DTAC-V3 in U251 Glioblastoma Cells. Left: U251 cells were treated with control, DNA-E3i, DNA-POIi, or DTAC-V3 (all at 100 nM) for specified durations. Cell survival rates were measured using the CCK-8 assay. Right: Enhanced inhibition of U251 cell growth by DTAC-V3 after a 3-day treatment period. Data represent mean values ± SD from two independent experiments, each with six technical replicates.

[0069] FIG. 22. Antitumor Efficacy of DTAC-V3 in U251 Glioblastoma Cells. U251 cells were treated with control, DNA-E3i, DNA-POIi, or DTAC-V3 (all at 100 nM) and colony formation was determined.

[0070] FIG. 23. Schematic illustration of PROGENTAC using light activation. First- generation PROGENT AC design showing proof-of-concept activation and release of intended ASO (blocker strand) using a UV / Visible light (365-500 nm) or chemical / biological stimuli. A First Strand contains the E3-inhibitor and NPOM small molecule which cannot hybridize with the complementary a Second Strand due to steric hinderance of NPOM group, a Second Strand contains a PC linker and hybridizes with itself in the self-complementary regions together they form inactive state. Addition of 365-400 nm light on inactive state, cleaves the NPOM steric group and PC linker, releasing the blocker strand and simultaneously forming the active PROGENTAC.

[0071] FIG. 24. DNA sequence design to demonstrate conditional activation and release of blocker. A First Strand contains a PC linker between the two self-complementary regions. Shown in the structure of the PC linker (photochemical linker). A Second Strand contains 1 to 5 NPOM, represented with T(m) small molecules internally. Shown is the chemical structure of the (m) (NPOM) linkage. The sequences of Strandl and A Second Strand are as follows:

[0072] A First Strand: TAG TAT GGT AGT GG - PC Linker - CCA CTAC CCT TCA TCT CCC ATC C (SEQ ID NOS 15 and 16)

[0073] A Second Strand: GGA TGG GAG ATG AAG GGT(m) AGT(m) AT(m)G GT(m)A GT(m)G G (SEQ ID NO: 17)

[0074] FIG. 25A. ESLMS of A First Strand containing five NPOM. Incorporation of five NPOM, T(m) molecules in the a First Strand is confirmed. Exp mass: 10,956.3 Da and Obs mass: 10,956.258 Da.

[0075] FIG. 25B. ESLMS of A Second Strand containing a PC linker. Incorporation of a PC linker in the a Second Strand is confirmed. Exp mass: 13,885.0 Da and Obs mass: 13,886.040 Da.

[0076] FIG. 26. Optimization of NPOM photocleavage in A First Strand at 365 nm light. A decrease in molecule weight for a Second Strand can be analyzed using ESLMS upon photocleavage of steric groups from five NPOM in a First Strand upon light irradiance at different time intervals.

[0077] FIG. 27. NPOM photocleavage in A First Strand at 365 nm light observed from Osec to 5mins. A clear decrease in molecular weight was observed even within 30 sec indicating cleavage of NPOM steric groups. Exp mass:9,840 Da; Obs mass: 9,840.3 Da.

[0078] FIG. 28. Optimization of PC linker photocleavage in A Second Strand at 365 nm light. Two distinct masses at 9,271.132 Da (Exp: 9,271) and 4,615.29 Da (Exp: 4,615) was observed on ESLMS upon light irradiance on a Second Strand within 30secs confirming the cleavage of the PC linker.

[0079] FIG. 29. Optimization of PROGENTAC formation. Two distinct masses at 9,271.132 Da (Exp: 9,271) and 4,615.29 Da (Exp: 4,615) was observed on ESLMS upon light irradiance on a Second Strand within 30secs confirming the cleavage of the PC linker.

[0080] FIG. 30. Optimization of A Second Strand containing PC linker. Additional 5 nucleotides (the “ATTCT” sequence) were added to a Second Strand before PC linker as a loop and referred to as PC-control a Second Strand. Exp mass: 15,400.95 Da: Obs mass: 15,400.981 Da. The sequence of PC-control a Second Strand is below:

[0081] TAG TAT GGT AGT GGA TTC T (PC spacer) CCA CTA CCA TAC TAC CCT TCA TCT CCC ATC C (SEQ ID NOS 18 and 19)

[0082] FIG. 31. Optimization of A Second Strand containing PC linker. Additional 5 nucleotides were added to a Second Strand before PC linker as a loop and commonhybridization sequence is shuffled. Strand referred to as PC-1 a Second Strand.15,400.95 Da: Obs mass: 15,401.030 Da. The sequence of PC-1 a Second Strand is as follows:

[0083] TAT GGT TAG TGA GGA TTC T (PC spacer) C CTCAC TAA C CA TAC CCT TCA TCT CCC ATC C (SEQ ID NOS 20 and 21)

[0084] FIG. 32. Optimization of A Second Strand containing PC linker. Additional 7 nucleotides were added to a Second Strand before PC linker as a loop and referred to as PC-2 a Second Strand. Exp mass: 16,009.35 Da: Obs mass: 16,009.528 Da. The sequence of PC-2 a Second Strand is as follows:

[0085] TAG TAT GGT AGT GGA TTC TTT (PC spacer) CCA CTA CCA TAC TAC CCT TCA TCT CCC ATC C (SEQ ID NOS 22 and 19)

[0086] FIG. 33. Native PAGE assay to test formation of Inactive PROGENTAC. Lane 2 shows the formation of duplex upon annealing of a First Strand and 2 (without blocker), lane 3 shows a First Strand containing five NPOM, lane (4-6) shows a Second Strand (PC-control, PC- 1 and PC-2) and lane (7-9) clearly shows the formation of inactive state of PROGENTAC as a single clean band in the gel.

[0087] FIG. 34A. Optimization of PROGENTAC activation at 365 nm. Irradiation of 365 nm light leads to cleavage of steric groups on NPOM and PC linker to form hybridized active PROGENTAC with simultaneous release of blocker strand.

[0088] FIG. 34B. Native PAGE assay to test the photoactivation of PROGENTAC. Irradiation of 365 nm light at different time intervals from 10-60 sec leads to cleavage of steric groups on NPOM and PC linker to form hybridized active PROGENTAC with simultaneous release of blocker strand.

[0089] FIG. 35. Photo cytotoxicity test in cells at different time intervals at 365 nm light irradiation. Cell viability measurements clearly indicate no appreciable cell toxicity until 3 mins of 365 nm light irradiation. Compared to the 30s required for conditional activation of PROGENTAC, high cell viability confirms further in-vitro testing of PROGENTAC at visible light.

[0090] Certain Definitions

[0091] As used herein, the term “about” refers to the stated value and typical degrees of error of the measurement of said value. If not otherwise explicitly recited herein, the term “about” refers to any number within + / - 10% of the recited value.

[0092] The term “and / or” as used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example “A and / or B” isto be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just a out individually herein.

[0093] “Operably-linked” refers to the association two chemical moieties so that the function of one is affected by the other, e.g., an arrangement of elements wherein the components so described are configured so as to perform their usual function.

[0094] The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double- stranded form, made of monomers (nucleotides) containing a sugar, phosphate and a base that is either a purine or pyrimidine. Unless specifically limited, the term encompasses nucleic acids containing synthetic analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0095] The terms "nucleotide sequence", “polynucleic acid”, or “nucleic acid sequence” refer to a sequence of bases (purines and / or pyrimidines) in a polymer of DNA or RNA, which can be single- stranded or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases capable of incorporation into DNA or RNA polymers, and / or backbone modifications (e.g., a modified oligomer, such as a morpholino oligomer, phosphorodiamate morpholino oligomer or vivo-mopholino). The terms “oligo”, “oligonucleotide” and “oligomer” may be used interchangeably and refer to such sequences of purines and / or pyrimidines. The terms “modified oligos”, “modified oligonucleotides”, “modified oligomers”, “modified ribonucleosides” or “modified ribonucleotides” may be similarly used interchangeably, and refer to such sequences that contain synthetic, non-natural or altered bases and / or backbone modifications. In some embodiments, the modified oligos can comprise chemical modifications to the internucleotide phosphate linkages and / or to the backbone sugar.

[0096] Modified nucleotides can include or exclude: alkylated purines and / or pyrimidines; acylated purines and / or pyrimidines; or other heterocycles. These classes of pyrimidines and purines can include or exclude: pseudoisocytosine; N4, N4-ethanocytosine; 8- hydroxy-N6-methyladenine; 4-acetylcytosine, 5-(carboxy hydroxylmethyl) uracil; 5-fluorouracil; 5 -bromouracil; 5-carboxymethylaminomethyl-2-thiouracil; 5-carboxymethylamino methyl uracil;dihydrouracil; inosine; N6-isopentyl-adenine; 1 -methyladenine; 1-methylpseud methylguanine; 2,2-dimethylguanine; 2-methyladenine; 2-methylguanine; 3-methylcytosine; 5- me thy ley to sine; N6-methyladenine; 7-methylguanine; 5 -methylaminomethyl uracil; 5-methoxy amino methyl-2-thiouracil; P-D-mannosylqueosine; 5-methoxycarbonylmethyluracil; 5- methoxy uracil; 2-methylthio-N6-isopentenyladenine; uracil-5-oxyacetic acid methyl ester; psueouracil; 2-thiocytosine; 5-methyl-2 thiouracil, 2-thiouracil; 4-thiouracil; 5-methyluracil; N- uracil-5-oxyacetic acid methylester; uracil 5-oxyacetic acid; queosine; 2-thiocytosine; 5- propyluracil; 5 -propylcytosine; 5-ethyluracil; 5-ethylcytosine; 5 -butyluracil; 5 -pentyluracil; 5- pentylcytosine; and 2, 6, -diaminopurine; methylpsuedouracil; 1 -methylguanine; 1- me thy Icy to sine. Backbone modifications are can include or exclude: chemical modifications to the phosphate linkage (e.g., phosphorodiamidate, phosphorothioate (PS), N3’phosphoramidate (NP), boranophosphate, 2’,5’phosphodiester, amide-linked, phosphonoacetate (PACE), morpholino, peptide nucleic acid (PNA) and inverted linkages (5 ’-5’ and 3 ’-3’ linkages)) and sugar modifications (e.g., 2’-0-Me, UNA, LNA).

[0097] The oligonucleotides described herein may be synthesized using standard solid or solution phase synthesis methods. In certain embodiments, the oligonucleotides are synthesized using solid-phase phosphoramidite chemistry (U.S. Patent No. 6,773,885) with automated synthesizers. Chemical synthesis of nucleic acids allows for the production of various forms of the nucleic acids with modified linkages, chimeric compositions, and nonstandard bases or modifying groups attached in chosen places through the nucleic acid’s entire length.

[0098] The length of each nucleic acid strand is variable and depends on, for example, the purpose of each strand. In certain embodiments, the nucleic acid strands are about 10 nucleotides in length to about 20,000 nucleotides in length, about 15 nucleotides in length to about 10,000 nucleotides in length, about 15 to about 7500 nucleotides in length, about 3000 to about 7000 nucleotides in length, about 5000 to about 7000 nucleotides in length, about 1500 to about 6500 nucleotides in length, about 1000 to about 7000 nucleotides in length, about 5500 to about 6500 nucleotides in length, about 15 to about 5000 nucleotides in length, about 15 to about 4000 nucleotides in length, about 15 to about 3000 nucleotides in length, about 250 to about 3000 nucleotides in length, about 500 to about 3000 nucleotides in length, about 1000 to about 3000 nucleotides in length, or about 1500 to about 2500 nucleotides in length, or any length between any of the aforementioned values. In certain embodiments, the nucleic acid strand is about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100,about 200, about 300, about 400, about 500, about 600, about 700, about 800, a1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about 2600, about 2700, about 2800, about 2900, about 3000, about 3100, about 3200, about 3300, about 3400, about 3500, about 3600, about 3700, about 3800, about 3900, about 4000, about 4100, about 4200, about 4300, about 4400, about 4500, about 4600, about 4700, about 4800, about 4900, about 5000, about 5100, about 5200, about 5300, about 5400, about 5500, about 5600, about 5700, about 5800, about 5900, about 6000, about 6100, about 6200, about 6300, about 6400, about 6500, about 6600, about 6700, about 6800, about 6900, about 7000, about 7100, about 7200, about 7300, about 7400, about 7500, about 7600, about 7700, about 7800, about 7900, about 8000, about 8100, about 8200, about 8300, about 8400, about 8500, about 8600, about 8700, about 8800, about 8900, about 9000, about 9100, about 9200, about 9300, about 9400, about 9500, about 9600, about 9700, about 9800, about 9900, or about 100000 nucleotides in length.

[0099] In some embodiments, the nucleic acids strands are synthesized de novo using chemical or biological methods. The nucleic acids can be chemically synthesized in a step-wise manner. In some embodiments, the nucleic acids can be synthesized using the cyanoethyl phosphoramidite method (Beaucage, S. L., and Caruthers, M. H., Tet. Let. 22:1859,1981); nucleoside H-phosphonate method (Garegg et al., Tet. Let. 27:4051-4054,1986; Froehler et al., Nucl. Acid. Res. 14:5399-5407, 1986; Garegg et al., Tet. Let. 27:4055-4058, 1986, Gaffney et al., Tet. Let. 29:2619-2622,1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market, including the use of an in vitro transcription method. In some embodiments, the RNA strands of this discusre are synthesized de novo by transcription.

[0100] In certain embodiments, the nucleic acid sequence strands comprise one or more modified nucleic acids. The modified nucleic acids can be a modified ribonucleotide, modified ribonucleoside, modified nucleotide, or modified nucleotide. In some embodiments, the modified ribonucleoside can be selected from the RNA-incorporated from, in part, 5- Aminoallyluridine-5'-Triphosphate (Trilink, N-1062), or Biotin- 16-Aminoally luridine-5'- Triphosphate (Trilink, N-5005).

[0101] In some embodiments, the modified nucleic acid can comprise a click chemistry- adapted base, an aldehyde- adapted base, or a thiol-adapted base. The modified nucleic acid can comprise an amino-modified nucleic acid, which has been further modified (e.g., by thereactionof an NHS-linked functional group) with a functional group. In some a amino-modified nucleic acid is incorporated into the nucleic acid sequence by the addition of 5- Aminoallyluridine-5'-Triphosphate during a transcription step of forming the ssRNA sequence. In some embodiments, the amino-modifier nucleic acids are available from Glen Research, Inc. (Miravai, Inc., San Diego, CA), and can include or exclude a modified base made by a phosphoramidite selected from: Amino-Modifier C6 dC, Amino-Modifier C2 dT, AminoModifier C6 dT, Amino-Modifier C6 dA, N2-Amino-Modifier C6 dG, Fmoc Amino-Modifier C6 dT, Amino-Modifier Serinol Phosphoramidite, Amino-Modifier C6-U Phosphoramidite, 5'- Amino-Modifier 5, 5'-Amino-Modifier C6, 5'-DMS(O)MT-Amino-Modifier C6, 5'- AminoModifier C12, 5'-Amino-Modifier C6-TFA, 5'-Amino-Modifier TEG CE- Phosphoramidite, 5'- Amino-Modifier C3-TFA, 5'-Amino-Modifier C6-PDA, 5'-Amino-Modifier C12-PDA, and 5'- Amino-Modifier TEG PDA. NHS -functionalized, alkyl halide, or aryl halide-functionalized E3 ligase targeting binders or POI ligands can react with the amine functional group. The thiol- adapted base can comprise a thiol functional group. In some embodiments, the thiol functional group can include or exclude a modified base made by a phosphoramidite selected from: S-Bz- Thiol-Modifier C6-dT, 5'-Thiol-Modifier C6, Thiol-Modifier C6 S-S, and Dithiol Serinol Phosphoramidite. Thiol-functionalized or maleimide-functionalized E3 targeting binders or POI ligands can react with the thiolfunctional group. The aldehyde- adapted base can comprise an aldehyde functional group. In some embodiments, the aldehyde functional group can include or exclude a modified base made by a phosphoramidite selected from 5'-Aldehyde-Modifier C2 Phosphoramidite, 5-Formylindole-CE Phosphoramidite, or any of the aldehyde modifiers described in U.S. Patent No. 9,475,831, herein incorporated by reference. Modified E3 ligase targeting binders or POI ligands can be functionalized with a hydrazine or oxime to form imine bonds to the aldehyde functional group. In some embodiments, the click chemistry-based functional group can include or exclude a modified phosphoramidite selected from: Alkyne - Modifier Serinol Phosphoramidite, 5'-Hexynyl Phosphoramidite, TIPS-5-Ethynyl-dU-CE Phosphoramidite, 5-Ethynyl-dU-CE Phosphoramidite, C8-TMS-Alkyne-dT-CE Phosphoramidite, C8-TMS-Alkyne-dT-CE Phosphoramidite, C8-TMS-Alkyne-dT-CE Phosphoramidite, C8-Alkyne-dT-CE Phosphoramidite, 2’-O-Propargyl A(Bz)-3’- phosphoramidite, 2’-O-Propargyl G(iBu)-3’ -phosphoramidite, Alkyne dT phosphoramidite, Alkyne amidite, hydroxyprolinol, Palmityl-C6 amino Phosphoramidite, Alkyne phosphoramidite, 5'-terminal, Propargyl-PEG5-l-O-(b-cyanoethyl-N,N- diisopropyl)phosphoramidite, endo-BCN CE-phosphoramidite, DBCO-Serinol Phosphoramidite,5'-DBC0-TEG Phosphoramidite, or DBCO-dT-CE Phosphoramidite. Alkynyl-E3 ligase targeting binders or POI ligands can be reacted to azide-functional groups to conjugate the E3 ligase targeting binder and / or the POI ligand to the nucleic acid strand. Conversely, azide-functionalized E3 ligase targeting binders or POI ligands can be reacted to alkynyl- functional groups to conjugate the E3 ligase targeting binder and / or the POI ligand to the nucleic acid strand. Similar click-chemistry pairing can be employed to conjugate the cognate functional groups of the E3 ligase targeting binder and / or the POI ligand to the first or second strand nucleic acid sequence, respectively.

[0102] Certain embodiments of the invention encompass isolated or substantially purified nucleic acid compositions. In the context of the present invention, an "isolated" or "purified" DNA molecule or RNA molecule is a DNA molecule or RNA molecule that exists apart from its native environment and is therefore not a product of nature. An isolated DNA molecule or RNA molecule may exist in a purified form or may exist in a non-native environment such as, for example, a transgenic host cell. For example, an "isolated" or "purified" nucleic acid molecule is substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In one embodiment, an "isolated" nucleic acid is free of sequences that naturally flank the nucleic acid (z.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.

[0103] By “portion” or “fragment,” as it relates to a nucleic acid molecule, sequence or segment of the invention, when it is linked to other sequences for expression, is meant a sequence having at least 20 nucleotides, at least 150 nucleotides, or at least 400 nucleotides. If not employed for expressing, a “portion” or “fragment” means at least 9, at least 12, at least 15, or at least 20, consecutive nucleotides, e.g., probes and primers (oligonucleotides), corresponding to the nucleotide sequence of the nucleic acid molecules of the invention.

[0104] The phrase "hybridizing specifically to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture e.g., total cellular) DNA or RNA. "Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that is accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target nucleic acid sequence.

[0105] The term "complementary" as used herein refers to the broad concept of complementary base pairing between two nucleic acids aligned in an antisense position inrelation to each other. When a nucleotide position in both of the molecules is o< nucleotides normally capable of base pairing with each other, then the nucleic acids are considered to be complementary to each other at this position. Thus, two nucleic acids are substantially complementary to each other when at least about 50%, at least about 60%, or at least about 80% of corresponding positions in each of the molecules are occupied by nucleotides which normally base pair with each other (e.g., A:T (A:U for RNA) and G:C nucleotide pairs).

[0106] As used herein, the term "therapeutically effective amount" means an amount of a compound of the present invention that (i) treats the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (z.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (z.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and / or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the drug may prevent growth and / or kill existing cancer cells, it may be cytostatic and / or cytotoxic. For cancer therapy, efficacy can be measured, for example, by assessing the time to disease progression (TTP) and / or determining the response rate (RR).

[0107] As used herein, the term “subject” as used herein refers to humans, higher nonhuman primates, rodents, domestic, cows, horses, pigs, sheep, dogs and cats. In one embodiment, the subject is a human.

[0108] As used herein, the terms "treat" and "treatment" refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or decrease an undesired physiological change or disorder. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (z.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0109] The terms "cancer" and "cancerous" refer to or describe the phyj condition in mammals that is typically characterized by unregulated cell growth. A "tumor" comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small- cell lung cancer, non-small cell lung cancer ("NSCLC"), adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer. Gastric cancer, as used herein, includes stomach cancer, which can develop in any part of the stomach and may spread throughout the stomach and to other organs; particularly the esophagus, lungs, lymph nodes, and the liver.

[0110] E3 Ligase Targeting Agents

[0111] E3 ligase targeting agents are small molecules to which E3 ligase preferentially binds. E3 ligase agents can include or exclude agents to cereblon (CRBN), von Hippel-Lindau ligand (VHL), and Inhibitor of Apoptosis Proteins (IAP). E3 ligase targeting agents can be chemically modified by the representative methods described herein to include a linkage to a modified base or nucleotide or nucleoside as described herein. The modified base or nucleotide or nucleoside conjugated to the E3 ligase targeting agent is part of the sequence of the first or second nucleic acid strands described herein.

[0112] In some embodiments, the E3 ligase targeting agent is selected from: pomalidomide, lenalidomide, nutlin-3, idasanutlin, Iberdomide (CC-220), LLL161, TD-106, PG, CC-885, eragidomide, thalidomide, VH032, VL285, VH298, VH101, VHL-e, PT-179, VHL ligand 14, cemsidomide, golcadomide, ALV2, VH032-cyclopropane-F, bestatin, A410099, or SPP-0636457. In some embodiments, thje E3 ligase targeting agent can be any of those disclosed in J. Lee, et al. Molecules, 2022, 27( 19):6515; or Bricelj A, Steinebach C, Kuchta R, Giitschow M, Sosic I. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points. Front Chem. 2021 Jul 5;9:707317. doi: 10.3389 / fchem.2021.707317. PMID: 34291038; PMCID: PMC8287636.

[0113] Protein of Interest Ligand

[0114] The protein of interest (POI) ligand can be any small molecule d the appropriate attachment sites amendable for the chemical modification (e.g., amine, azide, alkyne, carboxylic acid, methyl ester, electrophilic site, nucleophilic site, or hydroxyl) to covalently link the drug to a modified base by the representative methods described herein. The POI ligand can be a therapeutic agent as described herein. The POI ligand can be hydrophobic or hydrophilic. The POI generally has a molecular mass of less than 1200 Da, of less than 1000 Da, or less than 800 Da.

[0115] In some embodiments, the nucleic acid strand can be covalently connected to an agent. The agent can be selected from a diagnostic agent or a therapeutic agent. In certain embodiments, at least one diagnostic agent is operably linked to the nucleic acid strands. In certain embodiments, at least one diagnostic agent is operably linked to a modified base within the nucleic acid strand. In certain embodiments, at least one therapeutic agent is operably linked to the nucleic acid strand. In certain embodiments, at least one diagnostic agent and at least one therapeutic agent are operably linked to the SDTAC.

[0116] Diagnostic agents include imaging agents, e.g., fluorophores, radioisotopes, and colorimetric indicators.

[0117] As used herein, the term “therapeutic agent” includes agents that provide a therapeutically desirable effect when administered to subject. The agent may be of natural or synthetic origin. For example, it may be a nucleic acid, a polypeptide, a protein, a peptide, a radioisotope, saccharide or polysaccharide or an organic compound, such as a small molecule. The term “small molecule” includes organic molecules having a molecular weight of less than about, e.g., 1000 daltons. In one embodiment a small molecule can have a molecular weight of less than about 800 daltons. In another embodiment a small molecule can have a molecular weight of less than about 500 daltons.

[0118] In certain embodiments, the therapeutic agent is an immuno- stimulatory agent, a radioisotope, a chemotherapeutic drug (e.g., doxorubicin) or an immuno-therapy agent, such as antibody or an antibody fragment. In certain embodiments, the therapeutic agent is a vaccine, such as a cancer vaccine. In certain embodiments, the therapeutic agent is a tumor targeting agent, such as a monoclonal tumor- specific antibody or an aptamer. In certain embodiments, the therapeutic agent is an antibody or fragment thereof. The antibody or fragment thereof can be selected from a monoclonal antibody, a polyclonal antibody, an ScFv, or a nanobody. In some embodiments, the antibody is an anti-PDl antibody as described herein. In certain embodiments, the therapeutic agent is an antigen (e.g., a tumor associated antigen or a tumorspecific antigen). In certain embodiments, the therapeutic agent is one or more peptide(s).

[0119] In some embodiments, the therapeutic agent is a chemotherapeutic agent. As used herein, the term "chemotherapeutic agent" refers to a biological (large molecule) or chemical (small molecule) compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, proteins, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in “targeted therapy” and non-targeted conventional chemotherapy.

[0120] DNA-Based Prodrugs

[0121] In some embodiments, the complexes of this disclosure can include a DNA-based prodrug. DNA-based prodrugs can include or exclude a DNAzyme. The DNAzyme is a RNA- cleaving DNA enzyme which is a gene- silencing agent. The DNAzyme can include or exclude those described in U.S. Patent Nos. U.S. 11879140, U.S. 8815782, U.S. 8476245, U.S. 8815782, U.S. Patent Application Nos. US20040209263, US20050064407, US20040220123, US20090010907, PCT Publications W02023017501, WO2024105654, W02000009673, W02000009672, W02001011023, Nguyen, K., et al., Chemical evolution of an autonomous DNAzyme with allele- specific gene silencing activity. Nat Commun 14, 2413 (2023). doi.org / 10.1038 / s41467-023-38100-9; Larcher LM, et al., DNAzymes: Expanding the Potential of Nucleic Acid Therapeutics. Nucleic Acid Ther. 2023 Jun;33(3):178-192. doi: 10.1089 / nat.2022.0066. Epub 2023 Apr 21. PMID: 37093127; PMCID: PMC1027802, each of which are herein incorporated by reference).

[0122] In some aspects, the DNAzyme can include a xeno-nucleic acid modififed DNAzyme (Wang, Y., et al. A biologically stable DNAzyme that efficiently silences gene expression in cells. Nat. Chem. 13, 319-326 (2021). / doi.org / 10.1038 / s41557-021-00645-x, herein incorporated by reference).

[0123] In some embodiments, the DNA-based prodrug can be a macumolecular prodrug as described in Kruger F, et al., Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues. Adv Sci (Weinh). 2019 Jan 28 ;6(6): 1802095. doi: 10.1002 / advs.201802095. PMID: 30937274; PMCID: PMC6425433; Debart F, Dupouy C, Vasseur JJ. Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing. Beilstein J Org Chem. 2018 Feb 19;14:436-469. doi: 10.3762 / bjoc.14.32. PMID: 29520308;PMCID: PMC5827813; US7964580, US 10745435, US 11479576, US2023000I US20210139525, each of which is herein incorporated by reference).

[0124] In some embodiments, the DNA-based prodrug can be a antisense oligonucleotide (ASO).

[0125] Certain Compositions

[0126] In some aspects, this invention provides for a PROGENTAC, wherein the PROGENTAC comprises a nucleic acid sequence which comprises a modified nucleic acid. The modified nucleic acid can comprise an alkyl amine functional group.

[0127] In some aspects, this invention provides for a pharmaceutical composition comprising a PROGENTAC described herein and a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition further comprises at least one therapeutic agent.

[0128] In some aspects, this invention provides for a method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PROGENTAC or composition comprising such as described herein. In some aspects, the cancer is breast cancer, ovarian cancer, melanoma or lung cancer.

[0129] In some aspects, this invention provides for a method of inhibiting tumor growth in a subject, comprising administering to the subject a therapeutically effective amount of a composition described herein.

[0130] In some aspects, this invention provides for the use of the PROGENTAC as described herein or a composition as described herein for the manufacture of a medicament for inducing a tumor necrosis response in a subject.

[0131] In some aspects, this invention provides for the use of the PROGENTAC as described as described herein or a composition as described herein for inducing a tumor necrosis response.

[0132] In some aspects, this invention provides for the use of the PROGENTAC as described as described herein or a composition as described herein for the prophylactic or therapeutic treatment a disease or disorder.

[0133] In certain aspects, the present invention provides a pharmaceutical composition comprising the PROGENTAC as described herein and a pharmaceutically acceptable carrier.

[0134] In certain aspects, the present invention provides a method of treating a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of the PROGENTAC or a composition as described herein.

[0135] In certain aspects, the present invention provides a method of in] growth in a subject, comprising administering to the subject a therapeutically effective amount of the PROGENT AC or composition as described herein.

[0136] In certain aspects, the present invention provides a use of the PROGENT AC or composition as described herein for the manufacture of a medicament for treating a disease or disorder in a subject.

[0137] In certain aspects, the present invention provides a use of the PROGENT AC or composition as described herein for the prophylactic or therapeutic treatment of a disease or disorder.

[0138] In certain aspects, the present invention provides a kit comprising the PROGENTAC as described herein and instructions for administering the PROGENT AC to a subject to treat a disease or disorder.

[0139] The invention also provides processes disclosed herein that are useful for preparing an PROGENT ACs described herein.

[0140] In certain embodiments, the PROGENTAC comprises, consists essentially of, or consists of a single ssRNA molecule (z.e., one unimolecular oligonucleotide / polynucleotide strand). In certain embodiments, the PROGENTAC is assembled using a plurality of nucleic acid molecules (e.g., in certain embodiments two to ten nucleic acid molecules, preferably five nucleic acid molecules.

[0141] The length of each nucleic strand is variable and depends on, for example, the purpose of each strand. In certain embodiments, the nucleic acids of the PROGENTAC (z.e., oligonucleotide or RNA strand) are about 15 nucleotides in length to about 20,000 nucleotides in length, the ssRNA molecule (z.e., oligonucleotide or RNA strand) is about 15 nucleotides in length to about 10,000 nucleotides in length, about 15 to about 7500 nucleotides in length, about3000 to about 7000 nucleotides in length, about 5000 to about 7000 nucleotides in length, about1500 to about 6500 nucleotides in length, about 1000 to about 7000 nucleotides in length, about5500 to about 6500 nucleotides in length, about 15 to about 5000 nucleotides in length, about 15 to about 4000 nucleotides in length, about 15 to about 3000 nucleotides in length, about 250 to about 3000 nucleotides in length, about 500 to about 3000 nucleotides in length, about 1000 to about 3000 nucleotides in length, or about 1500 to about 2500 nucleotides in length. In certain embodiments, the ssRNA molecule (z.e., oligonucleotide or RNA strand) is about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400 about 2600, about 2700, about 2800, about 2900, about 3000, about 3100, about 3200, about 3300, about 3400, about 3500, about 3600, about 3700, about 3800, about 3900, about 4000, about 4100, about 4200, about 4300, about 4400, about 4500, about 4600, about 4700, about 4800, about 4900, about 5000, about 5100, about 5 5200, about 5300, about 5400, about 5500, about 5600, about 5700, about 5800, about 5900, about 6000, about 6100, about 6200, about 6300, about 6400, about 6500, about 6600, about 6700, about 6800, about 6900, about 7000, about 7100, about 7200, about 7300, about 7400, about 7500, about 7600, about 7700, about 7800, about 7900, about 8000, about 8100, about 8200, about 8300, about 8400, about 8500, about 8600, about 8700, about 8800, about 8900, about 9000, about 9100, about 9200, about9300, about 9400, about 9500, about 9600, about 9700, about 9800, about 9900, about 10000, about 10100, about 10200, about 10300, about 10400, about 10500, about 10600, about 10700, about 10800, about 10900, about 11000, about 11000, about 11100, about 11200, about 11300, about 11400, about 11500, about 11600, about 11700, about 11800, about 11900, about 12000, about 12100, about 12200, about 12300, about 12400, about 12500, about 12600, about 12700, about 12800, about 12900 nucleotides in length, about 13000 nucleotides in length, about 14000 nucleotides in length, about 15000 nucleotides in length, about 16000 nucleotides in length, about 17000 nucleotides in length, about 18000 nucleotides in length, about 19000 nucleotides in length, about 20000 nucleotides in length, about 25000 nucleotides in length, about 30000 nucleotides in length, about 35000 nucleotides in length, about 40000 nucleotides in length, about 45000 nucleotides in length, about 50000 nucleotides in length, about 75000 nucleotides in length, about 100000 nucleotides in length, about 125000 nucleotides in length, about 150000 nucleotides in length, about 175000 nucleotides in length or about 200000 nucleotides in length.

[0142] In some embodiments, the nucleic acids of the PROGENTAC are synthesized de novo using chemical or biological methods. The nucleic acids can be chemically synthesized in a step-wise manner. In some embodiments, the nucleic acids can be synthesized using the cyanoethyl phosphoramidite method (Beaucage, S. L., and Caruthers, M. H., Tet. Let.22:1859,1981); nucleoside H-phosphonate method (Garegg et al., Tet. Let. 27:4051-4054,1986; Eroehler et al., Nucl. Acid. Res. 14:5399-5407, 1986; Garegg et al., Tet. Let. 27:4055-4058, 1986, Gaffney et al., Tet. Let. 29:2619-2622,1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market, including the use of an in vitro transcription method. In some embodiments, the RNA strands of this discusre are synthesized de novo by transcription.

[0143] In certain embodiments, the PROGENTAC comprises one or m< nucleic acids. The modified nucleic acids can be a modified ribonucleotide or ribonucleoside. In some embodiments, the modified ribonucleoside can be selected from the RNA-incorporated from, in part, 5-Aminoallyluridine-5'-Triphosphate (Trilink, N-1062), or Biotin-16- Aminoallyluridine-5'-Triphosphate (Trilink, N-5005).

[0144] In some embodiments, the PROGENTAC can be connected to an agent. The agent can be selected from a diagnostic agents or therapeutic agents. In certain embodiments, at least one diagnostic agent is operably linked to the PROGENTAC. In certain embodiments, at least one diagnostic agent is operably linked to the tumor- specific antigen. In certain embodiments, at least one therapeutic agent is operably linked to the PROGENTAC. In certain embodiments, at least one therapeutic agent is operably linked to the tumor- specific antigen. In certain embodiments, at least one diagnostic agent and at least one therapeutic agent are operably linked to the PROGENTAC. In certain embodiments, at least one diagnostic agent and at least one therapeutic agent are operably linked to the tumor- specific antigen.

[0145] Diagnostic agents include imaging agents, e.g., fluorophores, radioisotopes, and colorimetric indicators.

[0146] As used herein, the term “therapeutic agent” includes agents that provide a therapeutically desirable effect when administered to subject. The agent may be of natural or synthetic origin. For example, it may be a nucleic acid, a polypeptide, a protein, a peptide, a radioisotope, saccharide or polysaccharide or an organic compound, such as a small molecule. The term “small molecule” includes organic molecules having a molecular weight of less than about, e.g., 1000 daltons. In one embodiment a small molecule can have a molecular weight of less than about 800 daltons. In another embodiment a small molecule can have a molecular weight of less than about 500 daltons.

[0147] In certain embodiments, the therapeutic agent is an immuno- stimulatory agent, a radioisotope, a chemotherapeutic drug (e.g., doxorubicin) or an immuno-therapy agent, such as antibody or an antibody fragment. In certain embodiments, the therapeutic agent is a vaccine, such as a cancer vaccine. In certain embodiments, the therapeutic agent is a tumor targeting agent, such as a monoclonal tumor- specific antibody or an aptamer. In certain embodiments, the therapeutic agent is an antibody or fragment thereof. The antibody or fragment thereof can be selected from a monoclonal antibody, a polyclonal antibody, an ScFv, or a nanobody. In some embodiments, the antibody is an anti-PDl antibody as described herein. In certain embodiments, the therapeutic agent is an antigen (e.g., a tumor associated antigen or a tumorspecific antigen). In certain embodiments, the therapeutic agent is one or more peptide(s).

[0148] In some embodiments, the therapeutic agent is a chemotherapeutic agent. As used herein, the term "chemotherapeutic agent" refers to a biological (large molecule) or chemical (small molecule) compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, proteins, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in “targeted therapy” and non-targeted conventional chemotherapy.

[0149] The immune system plays an important role in the development of a cancer cell from a normal cell. Thus, in some embodiments, the invention features a method comprising a PROGENTAC comprising an agent that targets one or more immune system checkpoints. Immune system checkpoints are inhibitory signaling pathways modulated by checkpoint proteins that turn off immune system effectors cells, for example, T cells. Some embodiments of the invention can include, checkpoint inhibitor antagonists (also referred to as “immune- checkpoint inhibitors antagonists”), which target the checkpoint proteins. The target checkpoint proteins include, but are not limited to, indoleamine (2, 3)-dioxygenase (IDO); programmed cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death- 1 (PD-1); programmed deathligand 1 (PD-L1); PD-L2; lymphocyte activation gene 3 (LAG3); and B7 homolog 3 (B7-H3).

[0150] In some embodiments, the checkpoint inhibitor antagonists bind to ligands or proteins that are found on any of the family of T cell regulators, such as CD28 / CTLA-4. Targets of checkpoint inhibitor antagonists include, but are not limited to, receptors or co-receptors (e.g., CTLA-4; CD8) expressed on immune system effector or regulator cells (e.g., T cells); proteins expressed on the surface of antigen-presenting cells (z.e., expressed on the surface of activated T cells, including PD-1, PD-2, PD-L1 and PD-L2); metabolic enzymes or metabolic enzymes that are expressed by both tumor and tumor- infiltrating cells (e.g., indoleamine (IDO), including isoforms, such as IDO1 and IDO2); proteins that belong to the immunoglobulin superfamily (e.g., lymphocyte-activation gene 3, also referred to as LAG3); proteins that belong to the B7 superfamily (e.g., B7-H3 or homologs thereof;). B7 proteins are found on both activated antigen presenting cells and T cells.

[0151] Checkpoint inhibitor antagonists useful in the present invention include but are not limited to: Ipilimumab (Yervoy), Tremelimumab (formerly ticilimumab), Pidilizumab (CT-Oi l), Nivolumab (BMS-936558), Lambrolizumab (MK-3475), MPDL3280A, IAMP-224, IMP321 (ImmuFact), MGA271, Indoximod, INCB024360, IMP321(Immuntep®), BMS-986016, LAG525, MBG453, CA-170, JNJ-6161O588, Endoblituzumab (MGA271), MGD009, 8H9, Lirilumab, IPH4102, CPI-444, MEDI9447, OMP-31M32, Trabedersen (AP12009), M7824, Galusertinib (LY2157299), IPI-549, Hu5F9-G4, TTI-621 (SIRPalphaFc), 9B12, MOXR 0916, PF08600, MEDI6383, MEDI0562, INCAGN01949, GSK3174998, TRX- 518, BMS-986156, AMG 228, MEDI1873, MEDI6469, MK-4166, INCAGN01876, GWN323, JTX-2011, GSK3359609, MEDI-570, Utomilumab, Urelumab, ARGX-110, BMS-936561, MDX-1203, Varilumab, CP-870893, APX005M, ADC- 1013, JNJ- 64457107, SEA-CD40, R07009789, BMX-986205, Indoximod, Epacadostat, MEDI9197, pixatimod, NKTR-214, CB- 1158, LTX-315, and AM0010.

[0152] In some embodiments, this invention provides for a PROGENT AC comprising a nucleic acid sequencing which comprises a modified ribonucleic acid. The modified ribonucleic acid can comprise an alkyl amine functional group. In some embodiments, the amino-modified ribonucleoside is incorporated into the RNA sequence by the addition of 5-Aminoallyluridine-5'- Triphosphate during a transcription step of forming the RNA sequence.

[0153] In some embodiments, this invention provides for a PROGENTAC which comprises a therapeutic agent. The therapeutic agent can be a small molecule drug or a protein or peptide. The protein or peptide is selected from thrombin, prothrombin, or mixtures thereof. In some embodiments, the protein or peptide is conjugated to the amino-modified nucleic acid backbone of the PROGENTAC by means of a cross -functional compound as described herein. In some embodiments, the maleimide group on the sulfo-SMCC can react to a cysteine on a non-reduced or reduced form of the protein or peptide, and the sulfosuccinimidyl group on the sulfo-SMCC can react to the amino-modified nucleotide. In some embodiments, the maleimide group on the sulfo-SMCC can react to a loading oligonucleotide which has been modified to include a thiol-group to form a loading oligonucleotide-functionalized agent.

[0154] KitsCertain embodiments of the invention also provide a composition comprising an PROGENTAC complex described herein and a carrier. In certain embodiments, the composition comprises a plurality of PROGENTAC and a carrier.

[0155] In certain embodiments, the composition further comprises at least one therapeutic agent as described herein.

[0156] In certain embodiments, the composition is a pharmaceutical coi carrier is a pharmaceutically acceptable carrier.

[0157] The present invention further provides kits for practicing the present methods. Accordingly, certain embodiments of the invention provide a kit comprising an PROGENT AC described herein and instructions for administering the PROGENTAC to treat a disease or condition. In certain embodiments, the kit further comprises a therapeutic agent described herein and instructions for administering the therapeutic agent in combination (e.g., simultaneously or sequentially) with the PROGENTAC.

[0158] Certain Methods

[0159] Certain embodiments of the invention also provide a method of treating a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of an PROGENTAC or a composition as described herein.

[0160] In certain embodiments, a method of the invention further comprises administering at least one therapeutic agent to the subject.

[0161] The at least one therapeutic agent may be administered in combination with the PROGENTAC. As used herein, the phrase “in combination” refers to the simultaneous or sequential administration of the PROGENTAC and the at least one therapeutic agent. For simultaneous administration, the PROGENTAC and the at least one therapeutic agent may be present in a single composition or may be separate (e.g., may be administered by the same or different routes).

[0162] Certain embodiments of the invention provide a PROGENTAC or a composition as described herein for use in medical therapy.

[0163] Certain embodiments of the invention provide the use of an PROGENTAC or a composition as described herein for the manufacture of a medicament for inducing an immune response in a subject (e.g., a mammal, such as a human).

[0164] Certain embodiments of the invention provide the use of an PROGENTAC or a composition as described herein for the manufacture of a medicament for inducing an immune response in a subject (e.g., a mammal, such as a human), in combination with at least one therapeutic agent.

[0165] Certain embodiments of the invention provide an PROGENTAC or a composition as described herein for inducing an immune response.

[0166] Certain embodiments of the invention provide an PROGENT AC composition as described herein for inducing an immune response, in combination with at least one therapeutic agent.

[0167] Certain embodiments of the invention provide the use of an PROGENTAC or a composition as described herein for the manufacture of a medicament for treating a disease or disorder in a subject.

[0168] Certain embodiments of the invention provide the use of PROGENTAC or a composition as described herein for the manufacture of a medicament for treating a disease or disorder in a subject, in combination with at least one therapeutic agent.

[0169] Certain embodiments of the invention provide an PROGENTAC or a composition as described herein for the prophylactic or therapeutic treatment a disease or disorder.

[0170] Certain embodiments of the invention provide an PROGENTAC or a composition as described herein for the prophylactic or therapeutic treatment of a disease or disorder, in combination with at least one therapeutic agent.

[0171] In certain embodiments, the disease or disorder is a condition that requires a boost of the host immunity. In certain embodiments, the disease or disorder is a hyperproliferative disorder, such as cancer. In certain embodiments, the disease or disorder is an infectious disease.

[0172] In certain embodiments, the cancer is carcinoma, lymphoma, blastoma, sarcoma, or leukemia. In certain embodiments, the cancer is a solid tumor cancer.

[0173] In certain embodiments, the cancer is squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, renal cell carcinoma, gastrointestinal cancer, gastric cancer, esophageal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer (e.g., endocrine resistant breast cancer), colon cancer, rectal cancer, lung cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, melanoma, leukemia, or head and neck cancer. In certain embodiments, the cancer is breast cancer.

[0174] In certain embodiments, the therapeutic agent is a therapeutic agent described herein. For example, in certain embodiments, the therapeutic agent is an immuno- stimulatory agent, a radioisotope, a chemotherapeutic drug (e.g., doxorubicin) or an immuno-therapy agent,such as antibody or an antibody fragment. In certain embodiments, the theraper vaccine, such as a cancer vaccine. In certain embodiments, the therapeutic agent is a tumor targeting agent, such as a monoclonal tumor- specific antibody or an aptamer. In certain embodiments, the therapeutic agent is an antibody (e.g., a monoclonal antibody, e.g., an anti- PD1 antibody). In certain embodiments, the therapeutic agent is an antigen (e.g., a tumor associated antigen or a tumor specific antigen). In certain embodiments, the therapeutic agent is a tumor antigen peptide(s).

[0175] Administration

[0176] In some embodiments, methods of the invention comprise administering a PROGENTAC described herein, and optionally, a therapeutic agent to a subject. Such PROGENTAC may be formulated as a pharmaceutical composition and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, intraperitoneal or topical or subcutaneous routes.

[0177] The PROGENTAC may be administered intravenously or intraperitoneally by infusion or injection. Solutions of the PROGENTAC or its salts is prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0178] The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle is a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity is maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms is brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride.Prolonged absorption of the injectable compositions is brought about by the use compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0179] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.

[0180] Pharmaceutical compositions for use in accordance with the present invention may be formulated using one or more physiologically acceptable carriers or excipients. Any suitable concentration of the PROGENT ACs may be used, and any active pharmaceutical ingredient will be administered in an amount effective to achieve its intended purpose.

[0181] A variety of suspending fluids or carriers may be employed to suspend the PROGENTACs composition. Such fluids include without limitation: sterile water, saline, buffer, or complex fluids derived from growth medium or other biological fluids. Preservatives, stabilizers and antibiotics may be employed in the PROGENTAC composition.

[0182] Methods of making a pharmaceutical composition include admixing at least one active compound or agent, as defined above, together with one or more other pharmaceutically acceptable ingredients, such as carriers, diluents, excipients, and the like. When formulated as discrete units, such as tablets or capsule or suspension, each unit contains a predetermined amount of the active compound or agent.

[0183] Suitable formulations will depend on the method of administration. The pharmaceutical composition is preferably administered by intradermal administration, but other routes of administration include for example oral, buccal, rectal, parenteral, intramuscular, subcutaneous, intraperitoneal, transdermal, intrathecal, nasal, intracheal. The polyvalent vaccine can also be administered to the lymph nodes such as axillary, inguinal or cervial lymph nodes. The active agent may be systemic after administration or may be localized by the use of regional administration, intramural administration, or use of an implant that acts to retain the active dose at the site of implantation.

[0184] Pharmaceutical compositions described herein may be administered directly, they mayalso be formulated to include at least one pharmaceutically-acceptable, nontoxi diluents, adjuvants, or non-toxic, nontherapeutic, fillers, buffers, preservatives, lubricants, solubilizers, surfactants, wetting agents, masking agents, and coloring agents. Also, as described herein, such formulation may also include other active agents, for example, other therapeutic or prophylactic agents, nonimmunogenic stabilizers, excipients and the like. The compositions can also include additional substances to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, wetting agents and detergents.

[0185] Useful dosages of nucleic acid complexes can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949, herein incorporated by reference.

[0186] The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

[0187] The nucleic acid complexes described herein may be conveniently formulated in unit dosage form. In one embodiment, the invention provides a composition comprising a nucleic acid complexes formulated in such a unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

[0188] Design of PROGENTAC.

[0189] Strategy 1: Sterically protected siRNA with conditional DTAC.

[0190] In some embodiments, this disclosure provides for a complex which affords the conditional activation of PROGENTAC through a single toehold mediated activation of both DTAC and siRNA. By leveraging the programmability and synthetic simplicity of DNA / RNA- based scaffolds, a novel dual-functioning system is capable of gene silencing through conditional siRNA release and protein degradation via the proteolysis pathway. This embodiment involves the utilization of five nucleic acid single strands: LI, L2, T, G, and P. Specifically, LI and L2 strands (ssDNA) can be functionalized with an E3 ligase targeting ligand and a ligand for binding the target protein, respectively. LI can be modified with thesmall molecule Pomalidomide and L2 with Palbociclib. In some embodiments,L2 can be modified with various small molecule drugs to degrade different types of proteins. The T strand is designed to act as a toehold / sensor strand, which, upon binding with mRNA, will activate the dual functions of ProGenTac. The hybridizing portion of strand T with L2 comprises deoxyribonucleotides, while its hybridizing portion with strand P will consist of ribonucleotides to prevent unintended cleavage by the RNase H enzyme and premature release of siRNA. Finally, strands P and G will be designed for siRNA loading, with both strands entirely composed of ribonucleotides. Annealing all the strands results in a structure containing inactive DTAC and siRNA components. The DTAC segment will initially be inactive due to a mismatch in the distance between the E3 and protein ligands. Similarly, siRNA will be rendered inactive due to the steric effects of the DTAC segment, preventing RNAi loading onto the siRNA . Once this system is triggered by external stimuli, such as mRNA, the DTAC and siRNA duplex will be released, with single- stranded nucleotide overhangs on both ends. The activated DTAC duplex will be responsible for protein degradation, while the released siRNA will undergo the process of forming the RISC complex. To safeguard the proposed PROGENTAC construct against nuclease degradation, all five DNA / RNA strands can be chemically stabilized using phosphorothioate, locked nucleic acid, and / or 2'-0Me modified nucleotides. The position and quantitative analysis of these synthetic modifications can be confirmed through chemical stability tests conducted in both in vivo and in vitro environments.

[0191] Strategy2: Conformationally protected siRNA with conditional DTAC.

[0192] In some embodiments, this disclosure provides for a complex which affords the unintended activation of siRNA by inducing conformational changes that alter its secondary structure. To achieve this, a short hairpin RNA (shRNA) is used which upon binding with the dicer enzyme in the cell cytoplasm, releases active siRNA by cleaving its 21 base pair stem regions. However, if the secondary structure of the stem part is altered, it will no longer be able to bind with dicer, thus preventing premature release of siRNA. Inspired by this mechanism, we propose our second design, where a conformationally altered shRNA secondary structure will be combined with an inactive DTAC structure. The toehold displacement triggered by mRNA releases both active DTAC and shRNA, which reorganizes to and form a 21 base pair stem- loop structure. The shRNA with the 21 base pair stem will bind with the Dicer enzyme, resulting in the eventual release of active siRNA as a product which can be used for gene regulation to treat a disease.

[0193] in vitro assessment of conditional activation of PROGENTAC.

[0194] A DNA-based PROTAC was created for the targeted degradatio which enables utilizing a DNA-based architecture for protein degradation. Recognizing that K- RAS can stimulate Cyclin DI expression, thus enhancing CDK4 / 6 activity Goel, Shorn, Johann S. Bergholz, and Jean J. Zhao. "Targeting CDK4 and CDK6 in cancer." Nature Reviews Cancer 22.6 (2022): 356-372; Fassl, Anne, Yan Geng, and Piotr Sicinski. "CDK4 and CDK6 kinases: From basic science to cancer therapy." Science 375.6577 (2022): eabcl495), the K-RAS gene was selected as the siRNA target for a demonstrative PROGENT AC system. The K-RAS siRNA has been seamlessly integrated with DTAC to form the PROGENTAC complex.

[0195] The PROGENTAC system becomes activated exclusively in the presence of specific overexpressed mRNA biomarkers in cancer cells. Upon activation, it liberates the DTAC to facilitate CDK4 / 6 degradation, while concurrently initiating the siRNA to silence K- RAS. This multi-faceted approach aims to mitigate the amplified upstream signals of CDK4 / 6 through siRNA, while concurrently fostering CDK4 / 6 degradation via the activated DTAC. By this mechanism, the PROGENTACs of this disclosure can effectively restrict cancer cell growth and proliferation, ultimately triggering apoptosis.

[0196] In one embodiment, a PROGENTAC can be constructed from DNA strands functionalized with E3 ligase-targeting ligands, targeted protein-binding ligands, and siRNA. Subsequently, the PROGENTAC structure will be hybridized together as per the design described herein. The system's activation can be confirmed through toehold sequence displacement using a FRET assay.

[0197] The PROGENTAC system can be transfected into pancreatic cancer cells to confirm he utility of the PROGENTACs for use in treating cancer. Post-transfection, the cells can be isolated and the protein expression levels measured of CDK4 / 6 and K-RAS via western blotting to confirm the knock-down effect on target CDK4 / 6 genes.

[0198] In some embodiments, the activation states of PROGENTAC can be measured by labeling the ligand- functionalized sites with fluorescent groups. Fluorescence quenching, instigated by the hybridization of the two ligand-containing chains upon PROTAC activation, will facilitate distinguishing between active and inactive states. Protein degradation fraction and siRNA alone can be used as controls under identical conditions, which allows for the comparison of the enhancement effect of the combined deployment of PROTAC and siRNA. Cell differentiation, growth and apoptosis analysis can also be used to measure the impact of representative PROGENTACs of this disclosure on tumorous cells under diverse treatmentconditions. The dual-action PROGENTAC system can exhibit a therapeutic str; cancer.Examples

[0199] The invention will now be illustrated by the following non-limiting Examples.

[0200] Example 1

[0201] Chemical synthesis and DTAC preparation

[0202] General Methods:

[0203] Unless noted otherwise, all non-aqueous reactions were conducted in oven-dried glassware under argon or nitrogen atmosphere. Reagents were commercially available and used without further purification, while anhydrous solvents were procured as the highest grade from Sigma- Aldrich. Thin-layer chromatography using 0.25 mm Silicycle silica gel 60 F254 plates was employed for reaction monitoring. Flash column chromatography utilized for small molecule purification using commercial 40-60 mesh silica gel column. Yields are presented as isolated yields of spectroscopically (NMR&LC / MS) pure compounds. 1H and 13C NMR spectra were acquired using 400 and 500 MHz Varian spectrometers. Chemical shifts are expressed in parts per million (ppm, 5) referenced to the residual 1H resonance of the solvent (CDC13, 7.26 ppm, and DMSO-d6, 2.49 ppm). 13C spectra are referenced to the residual 13C resonance of the solvent (CDC13, 77.16 ppm, and DMSO-d6, 39.52 ppm). Splitting patterns are denoted as follows: s, singlet; br, broad; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.

[0204] 4-((2-(2-(2-azidoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3- yDisoindoline- 1,3-dione (Azido-PEG3-pomalidomide; E3-i)

[0205] The Azido-PEG3-pomalidomide molecule was synthesized using previously published protocol with slight modification (FIG. 4).[1] 4-Fluorothalidomide (0.100 g, 0.362 mmol, 1 equiv.), Azido-PEG2-amine (0.082 g, 0.471 mmol, 1.3 equiv.), and N,N- Diisopropylethylamine (189 pL, 1.086 mmol, 3 equiv.) were added into anhydrous dimethyl sulfoxide (1 mL) and reaction mixture was heated 100°C for overnight under argon atmosphere. Thereafter solvent was co-evaporated with ethanol several times. The crude mixture was purified on a flash chromatography, eluting withEl hexane: ethylacetate (50:50) to obtain yellow-orange solid powder as a product: yield (0.095 g, 0.220 mmol, 61.03%); 1H NMR (500 MHz, CDC13) 5 8.51 (s, 1H), 7.49 (dd, J = 8.5, 7.1 Hz, 1H), 7.10 (d, J = 7.1 Hz, 1H), 6.92 (d, J = 8.5 Hz, 1H), 6.50 (t, J = 5.6 Hz, 1H), 5.00 - 4.89 (m, 1H), 3.74 (t, J = 5.4 Hz, 2H), 3.69 (d, J =4.1 Hz, 6H), 3.48 (q, J = 5.5 Hz, 2H), 3.38 (t, J = 5.0 Hz, 2H), 2.91 - 2.67 (m, 3= 9.7, 7.2, 3.1 Hz, 1H) (FIG. 5); QTOF-LC / MS (ESI+): m / z calculated for C19H22N6O6: 430.16. [M+Na]+; found 453.15 (FIG. 6).

[0206] 6-acetyl-2-((5-(4-(2-(2-(2-azidoethoxy)ethoxy)ethyl)piperazin-l-yl)pyridin-2- yl)amino)-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one (Azido-PEG3-palbociclib; POI-i)

[0207] Palbociclib (0.100 g, 0.223 mmol, 1 equiv.), Azide-PEG3-iodide (0.083 g, 0.290 mmol, 1.3 equiv.), Potassium carbonate (0.077 g, 0.558 mmol, 2.5 equiv.), and catalytic amount of Tetraethylammonium bromide (0.015 g, 0.045 mmol, 0.2 equiv.) were added into anhydrous dimethylformamide (2 mL) and reaction mixture was heated at 90°C for 6 hours under argon atmosphere (FIG. 7). After that reaction mixture was quenched with addition of distilled water (20 mL) and product was extracted with ethyl acetate (20 mL). Next, the organic phase was washed with brine, water and then dried over sodium sulfate for few minutes. Solvent was evaporated in reduced pressure and crude product was purified on a flash chromatography, eluting with 95:5 dichloromethane: methanol. Product was obtained as bright yellow solid: yield (0.07 g, 0.115 mmol, 52%) 1H NMR (500 MHz, CDC13) 5 8.86 (s, 1H), 8.62 (s, 1H), 8.15 (d, J = 9.1 Hz, 1H), 8.08 (d, J = 3.0 Hz, 1H), 7.33 (dd, J = 9.1, 3.0 Hz, 1H), 5.88 (q, J = 8.9 Hz, 1H), 3.68 (qd, J = 6.6, 3.6 Hz, 7H), 3.40 (t, J = 5.1 Hz, 2H), 3.22 (t, J = 5.0 Hz, 4H), 2.71 (dt, J = 15.8, 5.4 Hz, 5H), 2.55 (s, 3H), 2.38 (s, 5H), 2.17 - 2.00 (m, 2H), 1.96 - 1.83 (m, 2H), 1.75 - 1.58 (m, 2H), 1.26 (s, 1H) (FIG. 8A); QTOF-LC / MS (ESI+): m / z calculated for C30H40N1004: 604.32. [M+H]+; found 605.33 (FIG. 9).

[0208] Amine modified oligonucleotides synthesis and characterization.

[0209] The oligonucleotides were obtained via standard solid-phase oligonucleotide synthesis on a controlled pore glass (CPG, 1 pm). Standard DNA phosphoramidites, solid supports and additional reagents were purchased from Glen Research. The oligonucleotides were synthesized on an Applied Biosystems 3400 automated DNA / RNA synthesizer using a standard 1.0 pmole phosphoramidite cycle of acid-catalyzed detritylation activation and coupling, capping, and iodine oxidation. Stepwise coupling efficiencies and overall yields were determined by automated trityl cation conductivity monitoring. For phosphorothioate modification, 0.05M sulfurizing reagent II is prepared by dissolving in 40mL pyridine first, followed by 60mL acetonitrile to form a homogeneous solution. It is connected to the Auxiliary port on the DNA synthesizer and can be used similar to general iodine oxidation. For internal amine modification, amino-serinol phosphoramidite is dissolved in anhydrous acetonitrile to aconcentration of 0.1M immediately prior to use. Cleavage of the oligonucleotid support and deprotection was achieved by exposure to 30% ammonia solution for 120 minutes at 55 DC on a heating-block. The cleavage solutions were diluted with water and ammonia was removed by washing with water using a lOOkDa Amicon filter. The sequences of the oligonucleotides synthesized are tabulated below (where “i-NH2” denotes (FIG. 10) the internal amine and * represents phosphorothioate modifications) with the mass spectrometry data. The small molecule to be attached to each version is mentioned in brackets.

[0210] dibenzocyclooctyne (DBCO) modified oligonucleotides synthesis and characterization.

[0211] To conjugate DBCO to an oligonucleotide, an amine-modified DNA strand (Please see DNA sequences used) was treated with 6-fold excess of 200mM DBCO-sulfo-NHS- ester (dibenzocyclooctyne-sulfo-N-hydroxysuccinimidyl ester) in a 1XPBS buffer at pH ~8.5 (FIG. 1 IB). The mixture was gently shaken for 3h at 37°C. The DNA-DBCO conjugates were purified by 3kDa amicon filter at 8000 ref by repeated washing (5X) with distilled water to remove the excess small molecules and salts. Following filtration, the mixtures were purified using RP-HPLC and the conjugate peaks verified using ESI-MS.

[0212] Synthesis of E3-i and POI-i-DNA conjugates,

[0213] Conjugates were synthesized using strain promoted alkyne azide cycloaddition (SPAAC) chemistry (FIG. 11C), like previous reports. Briefly, to DNA-DBCO conjugates (in lxTAE-12.5mM MgC12, pH 7.5) was added 2 molar equivalents of 10 mM Azido-PEG3- pomalidomide (E3-i), or Azido-PEG3-palbociclib (POI-i) as a solution in DMSO. The reaction mixture was agitated and maintained at 37°C overnight. The DNA-drug conjugates were purified by 3kDa amicon filter at 8000 ref by repeated washing (5X) with distilled water to remove the excess small molecules and salts. Following reaction, the mixture was purified using RP-HPLC and the conjugate peaks verified using ESI-MS.

[0214] Purification by RP-HPLC.

[0215] Following reaction, small molecule-DNA conjugates were purified using a C-18 column on an Agilent 1220 Infinity LC HPLC. The mixtures were purified using a linear gradient method, with Buffer-A (50 mM triethylammonium acetate (TEAA)) and Buffer-B (methanol). A linear gradient was run from 10% to 100% Buffer B over 60 minutes. Conjugates were monitored and collected based on 260 nm (for DNA) and 309 nm (for DBCO) absorbances. Collected fractions were lyophilized overnight until dry.

[0216] Intact mass analysis of DTAC conjugates.

[0217] Collected peaks were tested for purity and identified by quadrup liquid chromatography mass spectrometry (QTOF LC / MS) analysis in the negative mode. A 50 uM solution is prepared from the stock of small molecule conjugated DNA strands for the analysis using 0.1% ammonium hydroxide as the mobile phase. Identified peaks are deconvoluted in the expected mass range to get the intact mass of the conjugates (FIGS. 12A- 13B). The sequences in were conjugated with respective ligand inhibitors for E3 ligase and Protein of interest (POI) to form DTAC-V1 to DTAC-V6.

[0218] Synthesis of DTAC versions.

[0219] All DTAC versions (1,2, 3, 4, 5, 6) were prepared by mixing site specifically modified ssDNA strands in equimolar ratio in 30 pL lxTAE-12.5 mM MgC12 buffer at 50 pM concentration. Thereafter reaction mixtures were annealed in a PCR thermocycler instrument using following protocol: Reaction mixtures were heated at 95 °C for 5 min and then quickly cooled to 4 °C (FIG. 14A).

[0220] PAGE analysis of DTAC conjugates,

[0221] Successfully synthesized DTAC library (FIG. 14B) was analyzed using 12% native polyacrylamide gel electrophoresis (PAGE). To each lane was added 10 pl of a 10 pM sample was added, and the gel was electrophoresed at 200 V (constant voltage) for 2.5 h at 10°C, then stained with ethidium bromide (EtBr) and imaged with a Bio-Rad Molecular Imager GelDOC XR+ imaging system (FIG. 15).

[0222] General biology methods

[0223] Cell culture

[0224] U-251 MG Glioblastoma Cell Line was grown in Dulbecco’s Modified Eagles Medium (DMEM) containing 10% heat inactivated fetal bovine serum (FBS), streptomycin (5 pg / mL) and 5 U / mL penicillin 95 U / mL). All cell lines were maintained, and cell culture experiments were carried out in humidified incubators at 37 degrees and 5% CO2 supplementation.

[0225] DTACs transfection

[0226] One day prior to DTACs transfection, cells were propagated into 6 cm cell culture dishes containing appropriate complete growth medium. Prior to transfection, complete medium was replaced with transfection medium (5%FBS, no Penstrep). DTACs transfection was performed using lipofectamine 3000 reagent according to the protocols provided by the manufacture. All transfections were carried out in 6-cm dishes with 3 mL of media and concentrations of DTACs were calculated according to this volume (3 mL). Briefly, for 50 nMconcentration, 5 |1L from a 3O|1M DTACs stock and 12 |1L p3000 reagent was ; containing 125 |1L of OPTIM-MEM and 8 |1L of Lipofectamine 3000 reagent was added to a separate tube containing 125 |1L of OPTIM-MEM. Two tubes were incubated for 5 minutes at room temperature and DTACs containing OPTI-MEM was then slowly added to the second tube with lipo3000. The solution in the tube was mixed well by pipetting up and down several times. After incubating for 15-20 minutes at room temperature, 250 |1L of DTACs-lipofectamine complex was added drop wise onto cells containing the transfection medium. Transfection medium was mixed well before transferring the plate into the incubator. After appropriate time, cells were either harvested or replaced with fresh medium and incubated for desired time point prior to harvesting.

[0227] The degradation efficiency of various DTACs was evaluated through their transfection into U251 cells, conducted simultaneously to ensure uniform experimental conditions. A double- stranded DNA sequence without any ligand was utilized as a negative control, providing a baseline for comparison. Following a 14-hour treatment period, a duration selected based on preliminary time-course studies, the cells were harvested using trypsin digestion. The lysates obtained were then subjected to SDS-PAGE, followed by Western blot analysis to assess protein degradation. As depicted in FIG. 16, DTAC-V3 exhibited the most pronounced degradation of CDK6 and CyclinDl. This was evidenced by the significantly reduced visibility of CDK6 and CyclnDl bands on the gel, in stark contrast to the control, at both 20 nM and 100 nM concentrations. This finding highlights the efficacy of DTAC-V3 in targeting and reducing CDK6 / CyclinDl protein levels. In comparison, DTAC-V1 also facilitated protein degradation, albeit with varying degrees of efficiency. Interestingly, DTAC- V6, characterized by the largest ligand distance of approximately 60.2 A, did not exhibit any discernible protein degradation at either concentration. These observations suggest that the spatial arrangement, specifically the distance between the E3 ligand and POI ligand, plays a critical role in influencing the protein degradation efficiency of DTACs. Based on these results, the structural configuration of DTACs, particularly the spatial relationship between their constituent ligands, is a key determinant in their ability to mediate CDK6 protein degradation.

[0228] Cyclin-dependent kinases (CDKs) typically form functional protein complexes through association with their cyclin partners. The distance library screening identified DTAC- V3 as the most effective compound for degrading both CDK6 and Cyclin DI proteins. Given that small molecule inhibitors of CDK6 can also bind with CDK4, we further investigated whether DTAC-V3 induces concurrent degradation of the CDK4 / 6 / Cyclin DI protein complex.To assess the efficacy of DTAC-V3 on the degradation of the CDK4 / 6 / Cyclin I conducted immunoblot analyses using U251 glioblastoma cells treated with various concentrations of DTAC-V3. The data reveal that DTAC-V3 induces a dose-dependent degradation of CDK4, CDK6, and Cyclin DI proteins (FIG. 17A). Additionally, to determine whether the degradation of these proteins occurs simultaneously, a time-course experiment was performed. U251 cells were treated with DTAC-V3 and harvested at different time points posttreatment (0, 2,4, 6, 12, 24, 36 and 48 hours). Immunoblot analysis demonstrated that degradation of CDK4, CDK6, and Cyclin DI proteins initiated at 4 hours post-treatment and persisted up to 48 hours (FIG. 17B). In summary, these findings indicate that DTAC-V3 effectively induces the simultaneous degradation of the CDK4 / 6 / Cyclin DI protein complex in a dose- and time-dependent manner.

[0229] To further validate the degradation of the CDK4 / 6 / Cyclin DI protein complex by DTAC-V3, we conducted a comparative experiment using a previously reported PROTAC, CP- 10, which is designed to degrade CDK4 and CDK6 but not Cyclin DI. CP- 10 is constructed using a chemical linker and incorporates the same pomalidomide (E3 ligase inhibitor, E3i) or palbociclib (CDK4 / 6 inhibitor, POIi) as DTAC-V3. U251 cells were treated with CP- 10 or palbociclib (CDK4 / 6 inhibitor, POIi) and the protein levels of CDK4, CDK6, and Cyclin DI were analyzed. As expected, treatment with CP- 10 or palbociclib did not result in the degradation of Cyclin DI, consistent with existing literature (FIG. 18). In contrast, treatment with DTAC-V3 led to a significant reduction in the protein levels of CDK4, CDK6, and Cyclin DI at concentrations of 20 nM and 100 nM (FIG. 18). These results highlight the superior efficacy of DTAC-V3 in targeting and degrading the entire CDK4 / 6 / Cyclin DI complex compared to CP- 10.

[0230] To investigate whether the ubiquitin-proteasome system (UPS) mediates the degradation of the CDK4 / 6 / Cyclin DI complex induced by DTAC-V3, we conducted rescue experiments using the proteasome inhibitors MG132 and PR171. U251 cells were pretreated with either MG132 or PR171 prior to DTAC-V3 exposure. The inhibition of the UPS by these proteasome inhibitors successfully prevented the degradation of CDK4 / 6 and Cyclin DI, suggesting that DTAC-V3 mediates protein degradation through the UPS pathway (FIG. 19). Furthermore, to confirm that DTAC-V3 facilitates CDK4 / 6 / Cyclin DI degradation via direct binding to CDK4 / 6 and subsequent recruitment of the CRBN E3 ligase, we performed ligand competition assays. U251 cells were simultaneously treated with DTAC-V3 and either the E3 ligase ligand pomalidomide or the CDK4 / 6 inhibitor palbociclib. The results demonstrated thatco-treatment with these ligands inhibited the degradation of CDK4, CDK6, and indicating that DTAC-V3 likely exerts its effects by engaging CDK4 / 6 and recruiting the CRBN E3 ligase for proteasomal degradation (FIG. 20). These findings collectively suggest that DTAC-V3 induces the degradation of the CDK4 / 6 / Cyclin DI complex through a mechanism involving the UPS, specifically by binding to CDK4 / 6 and recruiting the CRBN E3 ligase. This mechanistic insight supports the feasibility of DTAC-V3 as a therapeutic agent targeting CDK4 / 6 / Cyclin DI in cancer cells.

[0231] CDK4 (cyclin-dependent kinase 4) and CDK6 (cyclin-dependent kinase 6), when activated in complex with Cyclin DI, are critical for cell cycle progression from the G1 phase, where the cell grows and prepares for DNA replication, to the S phase, where DNA synthesis occurs. Dysregulation of the CDK4 / 6-Cyclin DI pathway is a common feature in various cancers, often due to overexpression or amplification of Cyclin DI or CDK4 / 6, leading to unchecked cell proliferation. Consequently, the CDK4 / 6-Cyclin DI complex has become a significant target for cancer therapeutics. Our previous data indicate that DTAC-V3 can significantly degrade the CDK4 / 6-Cyclin DI complex, potentially suppressing cancer cell growth. To validate this therapeutic effect, we conducted cell proliferation and colony formation assays. In the proliferation assays, cells were seeded in 96-well plates (5000 cells / well) and transfected with control, DNA-E3-i, DNA-POI-i, or DTAC-V3. Cell survival was assessed using the CCK-8 kit after designated intervals. Treatments with only DNA did not affect U251 cell proliferation, while those with either POI ligand or E3 ligand showed minor inhibitory effects. In contrast, DTAC-V3 treatment dramatically reduced U251 cell proliferation (FIG. 21). For the colony formation assays, cells were plated at 1000 cells / well in a 6-well plate and transfected with the same treatments every two days. After two to three weeks, cells were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet in 20% ethanol, and imaged. DTAC-V3 treatment consistently suppressed the colony formation of U251 cells, confirming its potent antiproliferative effects (FIG. 22).

[0232] The PROGENTAC design contains two strands (a First Strand and a Second Strand), which are chemically modified through in-house solid-state DNA synthesis. A First Strand, which is complementary to a Second Strand, was designed to contain five NPOM-caged thymine nucleobases. The thymine is caged with the photolabile 6-nitropiperonyloxymethyl (NPOM), which disrupts the binding of a First Strand with a Second Strand in the modified region. Therefore, the self-complementary region of a Second Strand can intramolecularly fold into a hairpin loop. A Second Strand is also modified with a photochemical spacer that can becleaved with the wavelength of UV light (365 nm), thus releasing the blocker si Second Strand. Upon exposure to 365-400 nm UV light, the photocaged NPOM groups can be removed from a First Strand and PC spacer get cleaved, triggering strand displacement and forming a duplex of a First Strand and a Second Strand. This phenomenon will allow conditional activation of DTAC and any gene silencing nucleic acid-based prodrugs.

[0233] The photo-uncaging and photo- splitting of a First Strand and a Second Strand, respectively, under 365 nm UV light was demonstrated. As shown in FIG. 27, within 30 seconds, all five NPOM-caged groups can be completely removed from a First Strand, resulting in a product mass of 9840.3 Da (FIG. 27). Similarly, upon exposing a Second Strand to 365 nm light, within 30 seconds, the PC linker is cleaved (FIG. 28), resulting in a product mass of 9271.132 Da for a Second Strand and a blocker strand mass of 4615.290 Da.

[0234] The self-assembly of the PROGENTAC design was analyzed using a native PAGE gel. As evident from the band shift, PROGENTAC (lanes 7, 8, and 9 from the left) forms a successful self-assembled structure composed of two strands: NPOM (a First Strand) and the PC strand (a Second Strand).

[0235] Embodiments of the PROGENTAC module can be activated at 365 nm light. PROGENTAC was exposed to 365 nm UV light for different time points, ranging from 10 seconds to 1 minute. As evident from the gel shift mobility in native PAGE (FIG. 34B), PROGENTAC gets activated within 10 seconds and forms two products (b. and c.). This demonstrates its rapid activation under UV light with short exposure.

[0236] A cell viability assay was performed to assess whether UV exposure induces cytotoxicity in cells. U-251 MG cells were pre-seeded into a 96-well plate at a density of 10,000 cells per well. On the following day, the cells were exposed to varying durations of UV light (365 nm) for 1 second, 30 seconds, 1 minute, or 3 minutes. Each exposure condition was performed in sextuplicate (six biological replicates). After an additional 48 hours of incubation, 10 pL of CCK-8 (Cell Counting Kit-8) solution was added to each well, and the plates were incubated for 2 hours. Optical density was then measured at 450 nm. Quantitative data from multiple repeats were analyzed using GraphPad Prism 10 and presented as means ± SEM. As illustrated in the figure, UV exposure did not cause toxicity to cells even under 3 minutes of exposure.

[0237] All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should beunderstood that many variations and modifications may be made while remaini: spirit and scope of the invention.

Claims

CLAIMSWhat is claimed is:

1. A system comprising: a. a first nucleic acid (NA) strand comprising: i. a first NA strand first sequence, and ii. a first NA strand second sequence; and b. a second nucleic acid strand comprising: i. a second NA strand first sequence, ii. a second NA strand second sequence, and iii. a second NA strand third sequence, wherein the first NA strand first sequence is hybridized to the second NA strand first sequence, wherein the first NA strand second sequence is complementary to the second NA strand second sequence, and the second NA strand third sequence is complementary to the second NA strand second sequence, wherein the first NA strand second sequence and the second NA strand second sequence independently comprise an E3 ligase targeting agent or a Protein of Interest (POI) ligand, and wherein when the first NA strand second sequence comprises an E3 ligase targeting agent the second NA strand second sequence comprises a POI ligand, and when the first NA strand second sequence comprises a POI ligand, the second NA strand second sequence comprises an E3 ligase targeting agent, wherein the second NA strand second sequence and the second NA strand third sequence are separated by a hairpin loop sequence or a selectively cleavable linker.

2. The system of claim 1, wherein the first NA strand comprises DNA.

3. The system of claim 1, wherein the second NA strand comprises DNA.

4. The system of claim 1, wherein the second NA strand second sequence is hybridized to the second NA strand third sequence to form an inactive complex.

5. The system of claim 4, wherein the POI ligand and the E3 ligase targeting agent are at complementary base positions.

6. The system of claim 1, wherein the first NA strand second sequence is hybridized to the second NA strand second sequence to form an active complex.

7. The system of claim 6, wherein the first NA strand second sequence is covalently hybridized to the second NA strand second sequence by photoclcavablc cross-links.

8. The system of claim 1, wherein the second NA strand third sequence is an antisense oligonucleotide or a nucleic acid-based prodrug.

9. A system comprising: a. a first nucleic acid (NA) strand comprising: i. a first NA strand first sequence, and ii. a first NA strand second sequence; and b. a second nucleic acid strand comprising: i. a second NA strand first sequence, and ii. a second NA strand second sequence, and c. a third strand NA sequence comprising: i. a third strand first sequence, ii. a third strand second sequence, and iii. a third strand third sequence; and d. a fourth strand NA sequence, wherein the first NA strand first sequence is hybridized to the second NA strand first sequence,wherein the first NA strand second sequence is complementary to the second NA strand second sequence, and the second NA strand third sequence is complementary to the second NA strand second sequence, wherein the first NA strand second sequence and the second NA strand second sequence independently comprise an E3 ligase targeting agent or a Protein of Interest (POI) ligand, and wherein when the first NA strand second sequence comprises an E3 ligase targeting agent the second NA strand second sequence comprises a POI ligand, and when the first NA strand second sequence comprises a POI ligand, the second NA strand second sequence comprises an E3 ligase targeting agent, and wherein the second NA strand second sequence is partially complementary to the third strand first sequence and the third strand second sequence in a splint-like manner, and wherein the third strand third sequence is complementary to the fourth strand NA sequence.

10. The system of claim 1, wherein the fourth NA strand is selected from siRNA or an antisense oligonucleotide sequence.

11. A method of killing a cancer cell, the method comprising: a. contacting a system of any of claims 1-10 in an inactive state with a cancer cell, b. converting the system in an inactive state to a system in an active state, thereby presenting an antisense oligonucleotide to the cancer cell.

12. The method of claim 11, wherein the antisense oligonucleotide is a knock-down sequence to the Protein of Interest.

13. The method of claim 11, wherein step (b) is performed by exposing UV light to the system.

14. The method of claim 13, wherein the UV light is at a wavelength of about 365 nm.

15. A composition comprising a system of any of claims 1-10 and a pharmaceutically acceptable carrier.

16. The composition of claim 15, further comprising a therapeutic agent.

Citation Information

Patent Citations

  • Compositions comprising circular polyribonucleotides for protein modulation and uses thereof

    US20220305128A1

  • Cereblon ligands and bifunctional compounds comprising the same

    US20230082997A1

  • Compounds for programmable protein degradation and methods of use for the disease treatment

    WO2022183006A1